Journal article icon

Journal article

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Abstract:

Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years. Methods In the worldwide Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, 12 894 women with early breast cancer who had completed 5 years of treatment with tamoxi...

Expand abstract

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Clinical Trial Service Unit, BHF Centre of Research Excellence
Role:
Author
Expand authors...
Journal:
The Lancet
Volume:
381
Issue:
9869
Pages:
805-816
Publication date:
2013-03-05
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
URN:
uuid:5f79fab4-e8e9-41d7-b8f8-2d0c04460f2f
Source identifiers:
389184
Local pid:
pubs:389184

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP